샘플 요청 목록

 카트 문의
시장보고서
상품코드
1637030

중증근무력증 치료 시장 - 세계 업계 분석, 규모, 점유율, 성장, 동향, 예측(2032년)

Myasthenia Gravis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032
발행일: | 리서치사: Fairfield Market Research | 페이지 정보: 영문 230 Pages | 배송안내 : 2-5일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 중증근무력증(MG) 치료 시장은 8.2%의 CAGR로 확대되며 큰 폭의 성장이 예상됩니다. 시장 규모는 2025년 26억 9,000만 달러에서 2032년 46억 7,000만 달러로 급증할 것으로 예상됩니다. 이러한 상승 궤적은 치료 방법의 기술적 진보와 중증근무력증에 대한 인식의 증가에 힘입은 바 큽니다.

중증근무력증(MG)은 신경근 자가면역질환으로 신경과 근육 사이의 정보전달 장애로 인해 근력저하와 피로를 유발하는 질환입니다. 치료의 주요 목표는 신경근 전달을 강화하고 자가면역 활동을 억제하는 것입니다. 사용 가능한 치료 전략에는 아세틸콜린에스테라아제 억제제, 면역 억제제, 혁신적인 단클론항체 요법 등이 있습니다.

특히 고령층의 MG 유병률 증가와 정밀의료에 대한 관심 증가는 시장 확대의 주요 요인으로 작용하고 있습니다. 또한, 제약기업과 연구기관의 공동연구를 통해 차세대 표적 치료제 개발이 빠르게 진행되고 있습니다.

에클리주맙과 리툭시맙과 같은 단클론항체는 특정 면역 성분을 표적으로 삼아 MG 치료에 혁명을 일으켜 보다 효과적인 질병 관리에 기여하고 있습니다. 면역치료의 지속적인 발전으로 복잡한 면역학적 요인에 대처할 수 있는 능력이 강화되어 보다 정확하고 효과적인 치료 옵션이 제공되고 있습니다.

세계의 중증근무력증 치료 시장에 대해 조사했으며, 시장 개요와 함께 약품 종류별, 유통 채널별, 지역별 동향, 시장 진입 기업의 경쟁 동향 등의 정보를 전해드립니다.

목차

제1장 주요 요약

제2장 시장 개요

  • 시장 정의와 세분화
  • 시장 역학
  • 밸류체인 분석
  • Porter's Five Forces 분석
  • COVID-19의 영향 분석
  • 우크라이나·러시아 분쟁의 영향
  • 경제 개요
  • PESTLE 분석

제3장 세계의 중증근무력증 치료 시장 전망, 2019-2032년

  • 세계의 중증근무력증 치료 시장 전망, 약물 종류별, 금액(10억 달러), 2019-2032년
  • 세계의 중증근무력증 치료 시장 전망, 유통 채널별, 금액(10억 달러), 2019-2032년
  • 세계의 중증근무력증 치료 시장 전망, 지역별, 금액(10억 달러), 2019-2032년

제4장 북미의 중증근무력증 치료 시장 전망, 2019-2032년

제5장 유럽의 중증근무력증 치료 시장 전망, 2019-2032년

제6장 아시아태평양의 중증근무력증 치료 시장 전망, 2019-2032년

제7장 라틴아메리카의 중증근무력증 치료 시장 전망, 2019-2032년

제8장 중동 및 아프리카의 중증근무력증 치료 시장 전망, 2019-2032년

제9장 경쟁 구도

  • 기업 시장 점유율 분석, 2025년
  • 경쟁 대시보드
  • 기업 개요
    • Grifols SA
    • Pfizer, Inc.
    • AbbVie Inc.
    • GSK
    • Novartis AG
    • Alexion Pharmaceutical Inc.
    • F. Hoffman-La Roche Ltd.
    • Bausch Health Companies Inc.
    • Shire plc.
    • Avadel Pharmaceuticals plc.

제10장 부록

KSM 25.02.11

The global myasthenia gravis (MG) treatment market is poised for substantial growth, with projections indicating an 8.2% compound annual growth rate (CAGR). The market size is expected to surge from USD 2.69 billion in 2025 to USD 4.67 billion by 2032. This upward trajectory is fueled by technological advancements in treatment methodologies and rising awareness about MG.

Overview of Myasthenia Gravis and Treatment Approaches

Myasthenia gravis (MG) is a neuromuscular autoimmune disorder that leads to muscle weakness and fatigue due to disrupted communication between nerves and muscles. The primary goal of treatment is to enhance neuromuscular transmission and suppress autoimmune activity. Available therapeutic strategies include acetylcholinesterase inhibitors, immunosuppressive drugs, and innovative monoclonal antibody therapies.

The increasing prevalence of MG, particularly among the aging demographic, and the growing focus on precision medicine are key drivers of market expansion. Moreover, collaborations between pharmaceutical companies and research institutions are fast-tracking the development of next-generation targeted treatments.

Key Market Growth Drivers

1. Breakthroughs in Immunotherapy

  • Monoclonal antibodies, such as eculizumab and rituximab, are revolutionizing MG treatment by targeting specific immune components, leading to more effective disease management.
  • Ongoing advancements in immunotherapy are enhancing the ability to address complex immunological factors, providing more precise and effective treatment options.

2. Increasing Awareness and Early Diagnosis

  • Enhanced diagnostic tools and public health initiatives are facilitating earlier detection of MG, improving patient outcomes.
  • Greater recognition among healthcare professionals and public awareness campaigns are boosting demand for effective treatment solutions.

Emerging Business Opportunities

1. Expansion of Personalized Treatment Strategies

  • Precision medicine is reshaping MG treatment by customizing therapies based on individual genetic profiles. This approach enhances treatment efficacy and minimizes side effects.
  • Advancements in immunogenetics and biotechnology are fostering the development of personalized therapeutic solutions.

2. Innovation in Treatment Modalities

  • Companies exploring new treatment avenues, such as gene therapies and advanced immunomodulators, have the potential to address unmet medical needs and unlock new revenue opportunities.
  • The adoption of next-generation biologics and novel drug formulations is reshaping the competitive Analysisof MG treatment.

Regional Market Insights

1. Europe: A Hub for Advanced MG Treatments

  • Europe leads the market due to its robust healthcare infrastructure and supportive regulatory framework.
  • Cutting-edge diagnostic facilities and specialized neurological care centers are driving rapid adoption of advanced MG treatments.
  • The European Medicines Agency's (EMA) proactive policies bolster investment confidence and accelerate drug development initiatives.

2. South Asia & Pacific: Fastest-Growing Market

  • Rapid population growth, along with an increasing prevalence of MG, is fueling demand for effective treatment solutions in this region.
  • Expanding healthcare access, coupled with rising awareness campaigns, is encouraging early diagnosis and treatment adoption.

Market Challenges and Barriers

1. Regulatory Hurdles

  • Stringent approval processes for new MG drugs can delay market entry, making regulatory compliance a critical challenge for pharmaceutical firms.
  • Companies must navigate complex approval requirements to maintain a competitive edge.

2. Complexity of MG Treatment

  • Due to MG's heterogeneous nature, treatment protocols must be personalized, making standardization difficult.
  • The need for individualized treatment plans increases the complexity of drug development and clinical trials.

Competitive Landscape: Key Industry Players

Several leading pharmaceutical companies are actively engaged in developing and commercializing MG treatments, including:

  • Alexion Pharmaceutical Inc.
  • Grifols SA
  • Avadel Pharmaceuticals plc.
  • Novartis AG
  • Pfizer Inc.
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Bausch Health Companies Inc.
  • Shire plc

These companies are investing in research and development (R&D) to introduce next-generation therapies and expand their market presence.

Market Segmentation: Key Categories

1. By Drug Class

  • Cholinesterase Inhibitors
  • Corticosteroids
  • Immunosuppressants
  • Intravenous Immunoglobulin (IVIg)
  • Monoclonal Antibodies

2. By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

3. By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Myasthenia Gravis Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2025
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Myasthenia Gravis Treatment Market Outlook, 2019 - 2032

  • 3.1. Global Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032
    • 3.1.1. Key Highlights
      • 3.1.1.1. Corticosteroids
      • 3.1.1.2. IVIg
      • 3.1.1.3. Monoclonal Antibodies
      • 3.1.1.4. Immunosuppressants
      • 3.1.1.5. Cholinesterase Inhibitors
  • 3.2. Global Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 3.2.1. Key Highlights
      • 3.2.1.1. Hospital Pharmacies
      • 3.2.1.2. Retail Pharmacies
      • 3.2.1.3. Online Pharmacies
  • 3.3. Global Myasthenia Gravis Treatment Market Outlook, by Region, Value (US$ Bn), 2019 - 2032
    • 3.3.1. Key Highlights
      • 3.3.1.1. North America
      • 3.3.1.2. Europe
      • 3.3.1.3. Asia Pacific
      • 3.3.1.4. Latin America
      • 3.3.1.5. Middle East & Africa

4. North America Myasthenia Gravis Treatment Market Outlook, 2019 - 2032

  • 4.1. North America Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032
    • 4.1.1. Key Highlights
      • 4.1.1.1. Corticosteroids
      • 4.1.1.2. IVIg
      • 4.1.1.3. Monoclonal Antibodies
      • 4.1.1.4. Immunosuppressants
      • 4.1.1.5. Cholinesterase Inhibitors
  • 4.2. North America Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 4.2.1. Key Highlights
      • 4.2.1.1. Hospital Pharmacies
      • 4.2.1.2. Retail Pharmacies
      • 4.2.1.3. Online Pharmacies
  • 4.3. North America Myasthenia Gravis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 4.3.1. Key Highlights
      • 4.3.1.1. Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 4.3.1.2. Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 4.3.1.3. Canada Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 4.3.1.4. Canada Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Myasthenia Gravis Treatment Market Outlook, 2019 - 2032

  • 5.1. Europe Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032
    • 5.1.1. Key Highlights
      • 5.1.1.1. Corticosteroids
      • 5.1.1.2. IVIg
      • 5.1.1.3. Monoclonal Antibodies
      • 5.1.1.4. Immunosuppressants
      • 5.1.1.5. Cholinesterase Inhibitors
  • 5.2. Europe Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 5.2.1. Key Highlights
      • 5.2.1.1. Hospital Pharmacies
      • 5.2.1.2. Retail Pharmacies
      • 5.2.1.3. Online Pharmacies
  • 5.3. Europe Myasthenia Gravis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 5.3.1. Key Highlights
      • 5.3.1.1. Germany Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 5.3.1.2. Germany Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.3.1.3. U.K. Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 5.3.1.4. U.K. Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.3.1.5. France Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 5.3.1.6. France Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.3.1.7. Italy Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 5.3.1.8. Italy Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.3.1.9. Turkey Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 5.3.1.10. Turkey Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.3.1.11. Russia Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 5.3.1.12. Russia Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.3.1.13. Rest of Europe Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 5.3.1.14. Rest of Europe Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Myasthenia Gravis Treatment Market Outlook, 2019 - 2032

  • 6.1. Asia Pacific Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032
    • 6.1.1. Key Highlights
      • 6.1.1.1. Corticosteroids
      • 6.1.1.2. IVIg
      • 6.1.1.3. Monoclonal Antibodies
      • 6.1.1.4. Immunosuppressants
      • 6.1.1.5. Cholinesterase Inhibitors
  • 6.2. Asia Pacific Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 6.2.1. Key Highlights
      • 6.2.1.1. Hospital Pharmacies
      • 6.2.1.2. Retail Pharmacies
      • 6.2.1.3. Online Pharmacies
  • 6.3. Asia Pacific Myasthenia Gravis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 6.3.1. Key Highlights
      • 6.3.1.1. China Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 6.3.1.2. China Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 6.3.1.3. Japan Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 6.3.1.4. Japan Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 6.3.1.5. South Korea Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 6.3.1.6. South Korea Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 6.3.1.7. India Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 6.3.1.8. India Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 6.3.1.9. Southeast Asia Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 6.3.1.10. Southeast Asia Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 6.3.1.11. Rest of Asia Pacific Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 6.3.1.12. Rest of Asia Pacific Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Myasthenia Gravis Treatment Market Outlook, 2019 - 2032

  • 7.1. Latin America Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032
    • 7.1.1. Key Highlights
      • 7.1.1.1. Corticosteroids
      • 7.1.1.2. IVIg
      • 7.1.1.3. Monoclonal Antibodies
      • 7.1.1.4. Immunosuppressants
      • 7.1.1.5. Cholinesterase Inhibitors
  • 7.2. Latin America Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 7.2.1. Key Highlights
      • 7.2.1.1. Hospital Pharmacies
      • 7.2.1.2. Retail Pharmacies
      • 7.2.1.3. Online Pharmacies
  • 7.3. Latin America Myasthenia Gravis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 7.3.1. Key Highlights
      • 7.3.1.1. Brazil Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 7.3.1.2. Brazil Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 7.3.1.3. Mexico Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 7.3.1.4. Mexico Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 7.3.1.5. Argentina Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 7.3.1.6. Argentina Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 7.3.1.7. Rest of Latin America Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 7.3.1.8. Rest of Latin America Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Myasthenia Gravis Treatment Market Outlook, 2019 - 2032

  • 8.1. Middle East & Africa Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032
    • 8.1.1. Key Highlights
      • 8.1.1.1. Corticosteroids
      • 8.1.1.2. IVIg
      • 8.1.1.3. Monoclonal Antibodies
      • 8.1.1.4. Immunosuppressants
      • 8.1.1.5. Cholinesterase Inhibitors
  • 8.2. Middle East & Africa Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 8.2.1. Key Highlights
      • 8.2.1.1. Hospital Pharmacies
      • 8.2.1.2. Retail Pharmacies
      • 8.2.1.3. Online Pharmacies
  • 8.3. Middle East & Africa Myasthenia Gravis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 8.3.1. Key Highlights
      • 8.3.1.1. GCC Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 8.3.1.2. GCC Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 8.3.1.3. South Africa Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 8.3.1.4. South Africa Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 8.3.1.5. Egypt Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 8.3.1.6. Egypt Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 8.3.1.7. Nigeria Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 8.3.1.8. Nigeria Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 8.3.1.9. Rest of Middle East & Africa Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 8.3.1.10. Rest of Middle East & Africa Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Market Share Analysis, 2025
  • 9.2. Competitive Dashboard
  • 9.3. Company Profiles
    • 9.3.1. Grifols SA
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Product Portfolio
      • 9.3.1.3. Financial Overview
      • 9.3.1.4. Business Strategies and Development
    • 9.3.2. Pfizer, Inc.
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Product Portfolio
      • 9.3.2.3. Financial Overview
      • 9.3.2.4. Business Strategies and Development
    • 9.3.3. AbbVie Inc.
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Product Portfolio
      • 9.3.3.3. Financial Overview
      • 9.3.3.4. Business Strategies and Development
    • 9.3.4. GSK
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Product Portfolio
      • 9.3.4.3. Financial Overview
      • 9.3.4.4. Business Strategies and Development
    • 9.3.5. Novartis AG
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Product Portfolio
      • 9.3.5.3. Financial Overview
      • 9.3.5.4. Business Strategies and Development
    • 9.3.6. Alexion Pharmaceutical Inc.
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Product Portfolio
      • 9.3.6.3. Financial Overview
      • 9.3.6.4. Business Strategies and Development
    • 9.3.7. F. Hoffman-La Roche Ltd.
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Product Portfolio
      • 9.3.7.3. Financial Overview
      • 9.3.7.4. Business Strategies and Development
    • 9.3.8. Bausch Health Companies Inc.
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Product Portfolio
      • 9.3.8.3. Financial Overview
      • 9.3.8.4. Business Strategies and Development
    • 9.3.9. Shire plc.
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Product Portfolio
      • 9.3.9.3. Financial Overview
      • 9.3.9.4. Business Strategies and Development
    • 9.3.10. Avadel Pharmaceuticals plc.
      • 9.3.10.1. Company Overview
      • 9.3.10.2. Product Portfolio
      • 9.3.10.3. Financial Overview
      • 9.3.10.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제